Please assess the completion status of the following clinical trial:

Trial Title: Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of migraines within the past year~* 1 to 8 moderate or severe migraine attacks per month in the past 2 months that lasted between 4 to 72 hours if untreated~* Use acceptable contraception throughout the study~* Able to complete the study questionnaire(s) and paper diary~* Limit consumption of grapefruit juice to no more than one 8 ounce glass a day~Exclusion Criteria:~* Pregnant or breast-feeding or is expecting to become pregnant during the study~* Difficulty distinguishing his/her migraine attacks from tension or interval headaches~* A history of mostly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours~* More than 15 headache-days per month or has taken medication for acute headache on more than 10 days a month in the past 3 months~* Greater than 50 years old at the age of migraine onset~* Previously taken telcagepant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telcagepant 140 mg (Type: EXPERIMENTAL): Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
- Telcagepant 280 mg (Type: EXPERIMENTAL): Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
- Control Group 1 (Type: PLACEBO_COMPARATOR): Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
- Control Group 2 (Type: PLACEBO_COMPARATOR): Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).